CL2020002568A1 - Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv - Google Patents
Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andvInfo
- Publication number
- CL2020002568A1 CL2020002568A1 CL2020002568A CL2020002568A CL2020002568A1 CL 2020002568 A1 CL2020002568 A1 CL 2020002568A1 CL 2020002568 A CL2020002568 A CL 2020002568A CL 2020002568 A CL2020002568 A CL 2020002568A CL 2020002568 A1 CL2020002568 A1 CL 2020002568A1
- Authority
- CL
- Chile
- Prior art keywords
- andv
- andesvirus
- expresses
- treating
- preventing
- Prior art date
Links
- 241000150489 Andes orthohantavirus Species 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 abstract 2
- 241000150452 Orthohantavirus Species 0.000 abstract 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 230000002612 cardiopulmonary effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 244000052637 human pathogen Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12111—Hantavirus, e.g. Hantaan virus
- C12N2760/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
La invención se refiere a una formulación inmunogénica que contiene la cepa Bacilo Calmette-Guerin (BCG) en una concentración entre 104-109 bacterias, que expresa al menos una proteína o fragmento inmunogénico de Andesvirus (ANDV), en una solución tampón salina farmacéuticamente aceptable, que sirve para preparar una vacuna útil para prevenir, tratar o atenuar infecciones de ANDV. ANDV pertenece a la familia de Hantavirus y es un patógeno humano altamente virulento, que afecta anualmente a decenas de personas en Chile generando en algunos infectados un Síndrome Cardiopulmonar por Hantavirus (SCPH).
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2020002568A CL2020002568A1 (es) | 2020-10-05 | 2020-10-05 | Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv |
CN202180076740.1A CN116615545A (zh) | 2020-10-05 | 2021-11-10 | 含有表达安第斯病毒(andv)蛋白的修饰的bcg菌株的、可用于预防和治疗汉坦-安第斯病毒感染的免疫原性制剂 |
PCT/CL2021/050107 WO2022073144A1 (es) | 2020-10-05 | 2021-11-10 | Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv |
US18/247,824 US20230390378A1 (en) | 2020-10-05 | 2021-11-10 | Immunogenic formulation containing a modified bcg strain expressing an andesvirus protein (andv) useful for preventing and treating hanta-andv virus infections |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2020002568A CL2020002568A1 (es) | 2020-10-05 | 2020-10-05 | Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002568A1 true CL2020002568A1 (es) | 2022-08-05 |
Family
ID=81125662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002568A CL2020002568A1 (es) | 2020-10-05 | 2020-10-05 | Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230390378A1 (es) |
CN (1) | CN116615545A (es) |
CL (1) | CL2020002568A1 (es) |
WO (1) | WO2022073144A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2016001238A1 (es) * | 2016-05-23 | 2018-01-19 | Fundación Ciencia Para La Vida | Fragmento de la proteína gc del género hantavirus que inhibe la fusión de dicho virus con una célula eucarionte, el cual consiste del dominio iii parcial putativo de gc, o de la región troncal parcial putativa de gc; composición farmacéutica que comprende el fragmento; y uso de dicho fragmento. |
US11602557B2 (en) * | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
CL2019003847A1 (es) * | 2019-12-26 | 2021-08-06 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv |
-
2020
- 2020-10-05 CL CL2020002568A patent/CL2020002568A1/es unknown
-
2021
- 2021-11-10 US US18/247,824 patent/US20230390378A1/en active Pending
- 2021-11-10 CN CN202180076740.1A patent/CN116615545A/zh active Pending
- 2021-11-10 WO PCT/CL2021/050107 patent/WO2022073144A1/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20230390378A1 (en) | 2023-12-07 |
CN116615545A (zh) | 2023-08-18 |
WO2022073144A1 (es) | 2022-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
DOP2023000187A (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
BR112022015764A2 (pt) | Construções de ácido nucleico, vetores, vírus do sarampo, composições imunogênicas, processos para recuperar o vírus do sarampo, moléculas de ácido nucleico, polipeptídeos, proteínas recombinantes, usos in vitro de um antígeno, métodos para tratar ou prevenir uma infecção e para induzir uma resposta imune protetora | |
CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
WO2021204825A3 (en) | INACTIVATED SARS-CoV-2 VIRUS VACCINE | |
CO2022012272A2 (es) | Vacunas contra el coronavirus y métodos de uso | |
WO2017156511A8 (en) | Live attenuated zika virus vaccine | |
CO2023003242A2 (es) | Vacuna contra el coronavirus y procedimiento para la preparación de la misma | |
CR20230312A (es) | Vacunas contra el vih y métodos de uso | |
CL2020002568A1 (es) | Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv | |
BR112023021654A2 (pt) | Vacina contra vírus | |
MX2022010781A (es) | Vacuna contra el virus sars-cov-2 con adyuvante cpg. | |
MX2022012527A (es) | Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria. | |
AR121940A1 (es) | Extracto de cocculus hirsutus para el tratamiento de la enfermedad por coronavirus 2019 (covid-19) | |
AR124040A1 (es) | Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv | |
AR120887A1 (es) | Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv | |
CL2023002490A1 (es) | Formulación inmunogénica con una o más cepas bcg modificadas que expresan una proteína de sars-cov-2 | |
CO2022015018A2 (es) | Métodos y medios para modificar la hemodinámica en infecciones | |
MX2022012165A (es) | Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19. | |
CL2013002829A1 (es) | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. | |
AR124491A1 (es) | FORMULACIÓN INMUNOGÉNICA QUE CONTIENE UNA O MÁS CEPAS BCG MODIFICADAS QUE EXPRESAN UNA PROTEÍNA DE SARS-CoV-2, ÚTIL PARA PREVENIR, TRATAR O ATENUAR EL DESARROLLO DE COVID-19 | |
AR123244A1 (es) | Vacuna de salmonella para el tratamiento de coronavirus | |
UY38933A (es) | Vacuna de partículas tipo virus del chicunguña y métodos para su uso | |
CO2022016537A2 (es) | Vacuna inactivada para sars-cov-2 y preparación de la misma | |
AR127807A1 (es) | Vacuna contra el coronavirus |